Patents by Inventor Laurence Anne Mevellec
Laurence Anne Mevellec has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101554Abstract: The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-dependent kinase 7 (CDK7) and to their use in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: September 24, 2021Publication date: March 28, 2024Inventors: Laurence Anne MEVELLEC, Sophie COUPA ép. DESCAMPS, Christophe Denis Pascal ADELINET, Yannick Aimé Eddy LIGNY, Christophe MEYER
-
Publication number: 20220177458Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as HPK1 inhibitors, useful for treating diseases such as cancer.Type: ApplicationFiled: March 24, 2020Publication date: June 9, 2022Inventors: Laurence Anne MEVELLEC, Jorge Eduardo VIALARD, Sophie COUPA, Christophe Denis Pascal ADELINET, Berthold WROBLOWSKI, James Patrick EDWARDS
-
Publication number: 20220169644Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as HPK1 inhibitors, useful for treating diseases such as cancer.Type: ApplicationFiled: March 24, 2020Publication date: June 2, 2022Inventors: Laurence Anne MEVELLEC, Jorge Eduardo VIALARD, Sophie COUPA, Christophe Denis Pascal ADELINET, Berthold WROBLOWSKI, James Patrick EDWARDS
-
Publication number: 20220135544Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: October 20, 2021Publication date: May 5, 2022Applicant: ASTEX THERAPEUTICS LTDInventors: Gordon SAXTY, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
-
Patent number: 10894793Abstract: The present invention relates to bicyclic pyridine, pyrazine, and pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: June 15, 2017Date of Patent: January 19, 2021Assignee: Janssen Pharmaceutica NVInventors: Didier Jean-Claude Berthelot, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquter, Isabelle Noelle Constance Pilatte, Virginie Sophie Poncelet, Olivier Alexis Georges Querolle
-
Publication number: 20200131153Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: October 25, 2019Publication date: April 30, 2020Applicant: ASTEX THERAPEUTICS LTDInventors: Gordon SAXTY, Christopher William MURRAY, Valerio BERDINI, Gilbert Ebai BESONG, Christopher Charles Frederick HAMLETT, Christopher Norbert JOHNSON, Steven John WOODHEAD, Michael READER, David Charles REES, Laurence Anne MEVELLEC, Patrick René ANGIBAUD, Eddy Jean Edgard FREYNE, Tom Cornelis Hortense GOVAERTS, Johan Erwin Edmond WEERTS, Timothy Pietro Suren PERERA, Ronaldus Arnodus Hendrika Joseph GILISSEN, Berthold WROBLOWSKI, Jean Fernand Armand LACRAMPE, Alexandra PAPANIKOS, Olivier Alexis Georges QUEROLLE, Elisabeth Thérèse Jeanne PASQUIER, Isabelle Noëlle Constance PILATTE, Pascal Ghislain André BONNET, Werner Constant Johan EMBRECHTS, Rhalid AKKARI, Lieven MEERPOEL
-
Patent number: 10519137Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: GrantFiled: November 13, 2017Date of Patent: December 31, 2019Assignee: ASTEX THERAPEUTICS LTDInventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Steven John Woodhead, Michael Reader, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Timothy Pietro Suren Perera, Berthold Wroblowski, Alexandra Papanikos, Olivier Alexis Georges Querolle, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
-
Publication number: 20190263804Abstract: The present invention relates to azabenzimidazole derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: ApplicationFiled: June 15, 2017Publication date: August 29, 2019Inventors: Isabelle Noelle Constance Pilatte, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquier, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Didier Jean-Claude Berthelot
-
Patent number: 10342795Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives of formula (I) and also compounds of formula (I?) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing novel compounds of the present invention, pharmaceutical compositions comprising compounds of the present invention as an active ingredient as well as the use of compounds of the present invention as a medicament.Type: GrantFiled: March 26, 2015Date of Patent: July 9, 2019Assignee: Janssen Pharmaceutica NVInventors: Laurence Anne Mevellec, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
-
Publication number: 20190169199Abstract: The present invention relates to bicyclic pyridine, pyrazine, and pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: ApplicationFiled: June 15, 2017Publication date: June 6, 2019Inventors: Didier Jean-Claude Berthelot, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquter, Isabelle Noelle Constance Pilatte, Birgine Sophie Poncelet, Olivier Alexis Georges Querolle
-
Patent number: 10280170Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: March 26, 2015Date of Patent: May 7, 2019Assignee: Janssen Pharmaceutica NVInventors: Laurence Anne Mevellec, Elisabeth Therese Jeanne Pasquier, Sophie Descamps, Guillaume Jean Maurice Mercey, Berthold Wroblowski, Jorge Eduardo Vialard, Lieven Meerpoel, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
-
Patent number: 10202387Abstract: The present invention relates to heterocyclyl linked imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: December 18, 2015Date of Patent: February 12, 2019Assignee: Janssen Pharmaceutica NVInventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
-
Patent number: 10087187Abstract: The present invention relates to substituted imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: December 18, 2015Date of Patent: October 2, 2018Assignee: Janssen Pharmaceutica NVInventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
-
Publication number: 20180127397Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: November 13, 2017Publication date: May 10, 2018Applicant: ASTEX THERAPEUTICS LTDInventors: Gordon SAXTY, Christopher William MURRAY, Valerio BERDINI, Gilbert Ebai BESONG, Christopher Charles Frederick HAMLETT, Christopher Norbert JOHNSON, Steven John WOODHEAD, Michael READER, David Charles REES, Laurence Anne MEVELLEC, Patrick René ANGIBAUD, Eddy Jean Edgard FREYNE, Tom Cornelis Hortense GOVAERTS, Johan Erwin Edmond WEERTS, Timothy Pietro Suren PERERA, Ronaldus Arnodus Hendrika Joseph GILISSEN, Berthold WROBLOWSKI, Jean Fernand Armand LACRAMPE, Alexandra PAPANIKOS, Olivier Alexis Georges QUEROLLE, Elisabeth Thérèse Jeanne PASQUIER, Isabelle Noëlle Constance PILATTE, Pascal Ghislain André BONNET, Werner Constant Johan EMBRECHTS, Rhalid AKKARI, Lieven MEERPOEL
-
Publication number: 20180057496Abstract: The present invention relates to heterocyclyl linked imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: ApplicationFiled: December 18, 2015Publication date: March 1, 2018Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
-
Publication number: 20180002336Abstract: The present invention relates to substituted imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: ApplicationFiled: December 18, 2015Publication date: January 4, 2018Applicant: Janssen Pharmaceutica NVInventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
-
Patent number: 9850228Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: GrantFiled: April 28, 2016Date of Patent: December 26, 2017Assignee: ASTEX THERAPEUTICS LTDInventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
-
Publication number: 20170173014Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives of formula (I) and also compounds of formula (I?) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: ApplicationFiled: March 26, 2015Publication date: June 22, 2017Applicant: JANSSEN PHARMACEUTICA NVInventors: Laurence Anne Mevellec, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
-
Publication number: 20170174690Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: ApplicationFiled: March 26, 2015Publication date: June 22, 2017Applicant: Janssen Pharmaceutica NVInventors: Laurence Anne Mevellec, Elisabeth Therese Jeanne Pasquier, Sophie Descamps, Guillaume Jean Maurice Mercey, Berthold Wroblowski, Jorge Eduardo Vialard, Lieven Mrrtpoel, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
-
Patent number: 9598396Abstract: The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization and their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and Y have defined meanings.Type: GrantFiled: August 18, 2015Date of Patent: March 21, 2017Assignee: Janssen Pharmaceutica NVInventors: Patrick Rene Angibaud, Laurence Anne Mevellec, Bruno Roux, Pierre-Henri Storck, Christophe Meyer, Jorge Eduardo Vialard